Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
Proceeds to fund global Phase 3 registration program for the company’s lead product candidate, Obexelimab, and support the clinical development of other pipeline programs Series B equity financing led by Enavate Sciences, a portfolio company of Patient Square Capital, also included new investors Longitude Capital and Vivo Capital WALTHAM, Mass.,